Meeting
2020 Genitourinary Cancers Symposium
Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment.
Authors
Nicholas Salgia
City of Hope Comprehensive Cancer Center, Duarte, CA
Nicholas Salgia , Nazli Dizman , Paulo Gustavo Bergerot , Cristiane Decat Bergerot , Joann Hsu , Sumanta K. Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 645)
Abstract #
645
Poster Bd #
E9
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.
First Author: Paolo Grassi
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu
Poster
2012 Genitourinary Cancers Symposium
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).
First Author: Daniel Yick Chin Heng
Poster
2012 Genitourinary Cancers Symposium
Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series.
First Author: Amber Flaherty